Nordea Investment Management AB Buys Shares of 38,078 Charles River Laboratories International, Inc. $CRL

Nordea Investment Management AB bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 38,078 shares of the medical research company’s stock, valued at approximately $5,636,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Allspring Global Investments Holdings LLC boosted its stake in Charles River Laboratories International by 29.1% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock valued at $353,750,000 after acquiring an additional 516,521 shares during the last quarter. Norges Bank acquired a new position in shares of Charles River Laboratories International in the 2nd quarter valued at $76,952,000. National Bank of Canada FI lifted its stake in shares of Charles River Laboratories International by 1,179.5% in the 2nd quarter. National Bank of Canada FI now owns 434,868 shares of the medical research company’s stock valued at $65,983,000 after purchasing an additional 400,881 shares during the period. Balyasny Asset Management L.P. boosted its position in shares of Charles River Laboratories International by 722.5% in the 2nd quarter. Balyasny Asset Management L.P. now owns 434,226 shares of the medical research company’s stock worth $65,885,000 after purchasing an additional 381,432 shares during the last quarter. Finally, Ariel Investments LLC grew its stake in shares of Charles River Laboratories International by 28.6% during the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock worth $214,751,000 after purchasing an additional 314,572 shares during the period. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Price Performance

NYSE CRL opened at $219.81 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37. The stock has a market cap of $10.82 billion, a price-to-earnings ratio of -140.90, a PEG ratio of 6.57 and a beta of 1.61. The business has a 50 day simple moving average of $191.81 and a 200 day simple moving average of $174.14. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $228.88.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $990.43 million. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The firm’s quarterly revenue was down .5% on a year-over-year basis. During the same period last year, the business posted $2.59 earnings per share. Analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Mizuho set a $215.00 target price on Charles River Laboratories International in a research note on Friday, January 9th. Wall Street Zen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Sunday, December 21st. Barclays lifted their price objective on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. JPMorgan Chase & Co. upped their target price on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. Finally, Evercore ISI increased their target price on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $209.46.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.